Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors

Basit Öğe Kaydı
dc.authorscopusidSaadettin Kılıçkap / 8665552100
dc.authorwosidSaadettin Kılıçkap / AAP-3732-2021
dc.contributor.authorKavgacı, Gözde
dc.contributor.authorGüven, Deniz Can
dc.contributor.authorKaygusuz, Yunus
dc.contributor.authorKaraca, Ece
dc.contributor.authorDizdar, Ömer
dc.contributor.authorKılıçkap, Saadettin
dc.contributor.authorAksoy, Sercan
dc.contributor.authorErman, Mustafa
dc.contributor.authorYalçın, Suayib
dc.date.accessioned2025-04-18T10:20:01Z
dc.date.available2025-04-18T10:20:01Z
dc.date.issued2024
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractPurpose This study aimed to assess the effects of concurrent opioid analgesic (OA) use with immune checkpoint inhibitors (ICIs) on progression-free survival (PFS) and overall survival (OS). Methods In this observational retrospective study, we included advanced cancer patients who received ICIs at Hacettepe University Hospital's Department of Medical Oncology between June 2018 and January 2023. Results Our study included 375 recurrent or metastatic cancer patients treated with ICIs in the first, second line, or beyond. There were no significant differences between the OA-treated and OA-untreated groups regarding median age, age group, gender, primary tumor location, ICI type, or the presence of baseline liver and lung metastases. However, the OA-treated group exhibited a significantly higher proportion of patients who had received three or more prior treatments before initiating ICIs (p = 0.015). OA-Untreatment was significantly correlated with prolonged mPFS (6.83 vs. 4.30 months, HR 0.59, 95% CI 0.44-0.79, p < 0.001) and mOS (17.05 vs. 7.68 months, HR 0.60, 95% CI 0.45-0.80, p < 0.001). Conclusions Our study demonstrates an association between the concurrent use of OAs and reduced OS and PFS in patients treated with ICIs. While OA treatment serves as a surrogate marker for higher disease burden, it may also suggest a potential biological relationship between opioids and immunotherapy efficacy.
dc.identifier.citationKavgaci, G., Guven, D. C., Kaygusuz, Y., Karaca, E., Dizdar, O., Kilickap, S., ... & Yalcin, S. (2024). Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors. Supportive Care in Cancer, 32(7), 467.
dc.identifier.doi10.1007/s00520-024-08681-2
dc.identifier.endpage7
dc.identifier.issn0941-4355
dc.identifier.issn1433-7339
dc.identifier.issue7
dc.identifier.scopus2-s2.0-85197161533
dc.identifier.scopusqualityQ1
dc.identifier.startpage1
dc.identifier.urihttp://dx.doi.org/10.1007/s00520-024-08681-2
dc.identifier.urihttps://hdl.handle.net/20.500.12713/7032
dc.identifier.volume32
dc.identifier.wosWOS:001258090600003
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.institutionauthorKılıçkap, Saadettin
dc.institutionauthoridSaadettin Kılıçkap / 0000-0003-1637-7390
dc.language.isoen
dc.publisherSpringer
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectImmune Checkpoint Inhibitors
dc.subjectOpioid Analgesics
dc.subjectCancer Pain Management
dc.subjectSurvival
dc.titleImpact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
s00520-024-08681-2.pdf
Boyut:
773.96 KB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu